Acute effects of angiotensin-converting enzyme inhibition versus angiotensin II receptor blockade on cardiac sympathetic activity in patients with heart failure

• Published in: American journal of physiology. Regulatory, integrative and comparative physiology Vol. 313; no. 4; pp. R410 - R417
• Main Authors: Azevedo, Eduardo R., Mak, Susanna, Floras, John S., Parker, John D.
• Format: Journal Article
• Language: English
• Published: United States American Physiological Society 01.10.2017
• Subjects: ACE inhibitors; Acute effects; Aged; Angiotensin II; Angiotensin Receptor Antagonists - pharmacology; Angiotensin Receptor Antagonists - therapeutic use; Angiotensin-converting enzyme inhibitors; Angiotensin-Converting Enzyme Inhibitors - pharmacology; Angiotensin-Converting Enzyme Inhibitors - therapeutic use; Blood pressure; Captopril; Captopril - pharmacology; Captopril - therapeutic use; Conversion; Effects; Female; Heart; Heart - drug effects; Heart - physiopathology; Heart diseases; Heart failure; Heart Failure - drug therapy; Heart Failure - physiopathology; Hemodynamics; Hemodynamics - drug effects; Hemodynamics - physiology; Homeostasis; Humans; Inhibitors; Kidneys; Losartan - pharmacology; Losartan - therapeutic use; Male; Middle Aged; Norepinephrine; Patients; Peptidyl-dipeptidase A; Pulmonary artery; Renin; Renin-Angiotensin System - drug effects; Renin-Angiotensin System - physiology; Sympathetic nervous system; Sympathetic Nervous System - drug effects; Sympathetic Nervous System - physiopathology; Treatment Outcome; cardiac sympathetic activity; congestive heart failure; angiotensin II

The beneficial effects of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II (ANG II) receptor antagonists in patients with heart failure secondary to reduced ejection fraction (HFrEF) are felt to result from prevention of the adverse effects of ANG II on systemic afterload and renal...